OSTARINE (MK-2866)
Ostarine MK-2886 is an, non-steroidal Selective Androgen Receptor Modulator (SARM) with tissue-selective anabolic and androgenic pharmacologic activity. It is also known in the literature as enbosarm, GTx-024 or S-22.
Originally discovered in 1998, by James T. Dalton, Duane D. Miller, Karen A. Veverka, and their research teams at Ohio State University, the University of Tennessee, and GTx, respectively. GTx licensed the use of enbosarm from those research teams and further licensed the development of MK2886 with Merck and Co.
MK-2886 is one of the first SARMS to be synthesized and studied in rats and primates. As a result, it is one of the most extensively researched SARMS.
One study was performed on the cellular level of adult rats, specifically the adipocytes or fat cells. With the administration of MK-2886 Ostarine, the expression of fat-mediating hormones like leptin and adiponectin mRNAs was decreased. Because of these effects, researchers concluded that MK-2886 Ostarine was likely to behave similarly to testosterone on the AR receptors and decrease the body fat of the rat. https://pubmed.ncbi.nlm.nih.gov/31642815/
In addition to fat loss potential, MK-2886 Ostarine has also been shown to stimulate bone growth in rats. One study removed a portion of the tibia from 4 groups of rats and then administered increasing levels of the SARM (0.04, 0.4, and 4mg/kg) over the course of 5 weeks. At the highest dosing level, 4mg/kg, the test subjects showed denser bone regrowth, increased healing time of the bone, and higher markers of bone growth hormones such as phosphorus and alkaline phosphatase.
Interestingly, all of the rats in the study group demonstrated an increased weight of the gastrocnemius muscle over rats who were not treated with MK-2886, even at the lowest dosing levels (0.04mg/kg, a decrease of 100 fold from the highest dosing group).
Serum cholesterol levels were also reduced in this treatment group and the median dose group (0.4mg/kg). The improved lipid profile of the mice was also noted in the earliest studies of MK-2886. https://pubmed.ncbi.nlm.nih.gov/31531719/
Another study yielded similar results, with rats with clinically induced osteoporosis showing increased bone density in the long bones (such as the femurs, bone growth was not noted in the vertebrae) in rats treated at moderate to high levels of MK 2866. https://pubmed.ncbi.nlm.nih.gov/29785666/
A third study specifically evaluated muscle growth in mice to evaluate the function of MK-2866 with mice who were genetically developed to be without traditional androgen receptors. Then by removing the mice’s endogenous testosterone-producing cells, they noted further muscle wasting and began MK-2886 treatment. These mice experienced muscle growth in androgen-sensitive muscles, indicating a separate pathway, distinct from sat ARKO that encouraged muscle growth at the same levels as DHT. – https://pubmed.ncbi.nlm.nih.gov/26393303/
Half Life
24 hours.
DISCLAIMER
This material is sold for use in laboratory research only. Terms of sale apply. Not for human consumption, nor for medical, veterinary or domestic use. Please familiarize yourself with our DISCLAIMER before ordering.
Data Sheet:
Ostarine (MK-2866) – Powder, 1gr
| Application | Selective Androgen Receptor Modulator |
| CAS | 841205-47-8 |
| Molar Mass | 389.33 g/mol |
| Chemical Formula | C19H14F3N3O3 |
| IUPAC Name | ((2S)-3-(4-cyanophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide) |
| Synonyms | Ostarine, Enobosarm, GTx-024, MK-2866 |
| Storage | Room temperature |
| Solubility | Soluble in PEG400, Ethanol |
| Organoleptic Profile | White crystalline powder |
| Physical Form | Solid |
| Specification | ≥98% |
| Terms | This material is sold for laboratory research use only. Terms of sale apply. Not for human consumption, nor medical, veterinary, or household uses. Please familiarize yourself with our Terms & Conditions prior to ordering. |